利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

640 条记录 (耗时 0.037 秒)

    Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
    42.
    发明授权
    Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody 有权
    抗人溶性纤维蛋白单克隆抗体和免疫测定法使用抗体

    公开(公告)号：US07829294B2

    公开(公告)日：2010-11-09

    申请号：US11722998

    申请日：2005-12-27

    申请人： Masanao Matsuo ,  Hiroyuki Ebinuma ,  Osamu Miyazaki ,  Kyoko Tanaka ,  Akiko Suzuki

    发明人： Masanao Matsuo ,  Hiroyuki Ebinuma ,  Osamu Miyazaki ,  Kyoko Tanaka ,  Akiko Suzuki

    IPC分类号： G01N33/543 ,  G01N33/573 ,  G01N33/577 ,  C07K16/36 ,  C12N5/20 ,  C12P21/08

    CPC分类号： C07K16/18 ,  C07K14/745 ,  C07K14/75 ,  G01N33/86 ,  G01N2333/75 ,  G01N2800/224

    摘要： The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an Aα-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.

    摘要翻译： 本发明涉及针对可溶性纤维蛋白的单克隆抗体，其特异性识别通过纤维蛋白原凝血酶消化形成的可溶性纤维蛋白的Aα链的C末端区域中新发生的构象改变部位。 本发明还涉及产生抗体的杂交瘤，使用抗体的免疫测定方法，以及通过使用测定方法测量样品中的可溶性纤维蛋白水平来评估测试样品中的高凝状态的方法。 通过使用本发明的单克隆抗体，可以特异性检测仅反映初始高凝状态的纤维蛋白溶酶未起作用的可溶性纤维蛋白。

    Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
    43.
    发明授权
    Peptides and peptide derivatives as well as pharmaceutical compositions containing the same 失效
    肽和肽衍生物以及含有它们的药物组合物

    公开(公告)号：US07799758B2

    公开(公告)日：2010-09-21

    申请号：US11678535

    申请日：2007-02-23

    申请人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

    发明人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

    IPC分类号： A61K38/16 ,  C07K14/00

    CPC分类号： C07K14/75 ,  A61K38/00 ,  Y02A50/385

    摘要： Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

    摘要翻译： 治疗组合物可以包括衍生自Bβ（15-42） - 纤维蛋白片段的链的修饰肽，并且其中序列的一个或几个氨基酸已被遗传编码的或未经遗传编码的氨基酸或肽模拟物取代。 它们可以作为游离肽或C末端衍生物存在和/或与聚乙二醇（PEG） - 聚合物连接，并具有抗炎和/或内皮稳定作用。 酯或酰胺可以例如被考虑为C末端衍生物。 还描述了肽及其衍生物的制备方法。

    Process For Producing Recombinant Fibrinogen Highly Producing Cell and Highly Producing Cell
    46.
    发明申请
    Process For Producing Recombinant Fibrinogen Highly Producing Cell and Highly Producing Cell 有权
    生产重组纤维蛋白原高产细胞和高产细胞的方法

    公开(公告)号：US20100151522A1

    公开(公告)日：2010-06-17

    申请号：US10566266

    申请日：2004-07-28

    申请人： Reiko Matsuyama ,  Hiroaki Maeda

    发明人： Reiko Matsuyama ,  Hiroaki Maeda

    IPC分类号： C12P21/04 ,  C12N15/87 ,  C12N5/06 ,  C07K14/00

    CPC分类号： C07K14/75

    摘要： When genes encoding three kinds of proteins constituting fibrinogen, an α chain (or variant of α chain), a β chain and a γ chain (or variant of γ chain) are incorporated into an animal cell, a constitutional ratio of respective genes is such that a γ chain (and/or variant of γ chain) gene is an equal amount to a 1000-fold amount relative to an α chain (and/or variant of α chain) gene and a β chain gene and, further, by using a baculovirus P35 gene, a recombinant fibrinogen highly producing cell is prepared.

    摘要翻译： 当编码构成纤维蛋白原的三种蛋白质的基因，α链（或α链的变体），a＆bgr; 链和γ链（或γ链的变体）并入动物细胞中，各基因的构成比例使得γ链（和/或γ链的变体）基因等于1000倍 相对于α链（和/或α链的变体）基因和bgr的量; 链基因，并且通过使用杆状病毒P35基因，制备重组纤维蛋白原高产细胞。

    PEPTIDES AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION
    47.
    发明申请
    PEPTIDES AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION 审中-公开
    其制备方法及其衍生物，其制备方法及其用于制备治疗性和/或预防性活性药物组合物的用途

    公开(公告)号：US20090286725A1

    公开(公告)日：2009-11-19

    申请号：US12121544

    申请日：2008-05-15

    申请人： Peter PETZELBAUER ,  Sonja REINGRUBER ,  Waltraud PASTEINER ,  Rainer HENNING

    发明人： Peter PETZELBAUER ,  Sonja REINGRUBER ,  Waltraud PASTEINER ,  Rainer HENNING

    IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P29/00 ,  C07K1/00

    CPC分类号： C07K14/75 ,  A61K38/00

    摘要： Peptides and peptide derivatives of the following general Formula I: (SEQ ID NO: 15) (I) H2N-GHRPX1X2X3X4X5X6X7X8PX9X10X11PX12PPPX13X14X15 X16GYR-X17, wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen or (C1-C10)-alkyl, as well as the physiologically acceptable salts thereof.

    摘要翻译： 以下通式I的肽和肽衍生物：（SEQ ID NO：15）（I）H 2 N-GHRPX1X2X3X4X5X6X7X8PX9X10X11PX12PPPX13X14X15 X16GYR-X17，其中：X1-X16表示20个遗传编码氨基酸之一，X17表示OR1，R1 = 氢或（C 1 -C 10 - 烷基）或NR 2 R 3，R 2和R 3相同或不同并且表示氢，（C 1 -C 10） - 烷基或残基-PEG 5 - 60K，其中所述PEG-残基连接到N 或者残基NH-YZ-PEG5-60K，其中Y表示S，C，K或R组中的化学键或遗传编码氨基酸，Z表示间隔基，通过其间隔， 可以连接聚乙二醇（PEG）残基以及其生理上可接受的盐，或其中：X 15或X 16表示与C或K基团相连的氨基酸，其与残基Z-PEG5-60K连接 并且其中X17表示OR1，其中R1 =氢或（C1-C10-烷基）或NR2R3，R2和R3相同或不同，并且de 注意氢或（C1-C10） - 烷基，以及其生理学上可接受的盐。

    Biocompatible crosslinked polymers with visualization agents
    48.
    发明授权
    Biocompatible crosslinked polymers with visualization agents 有权
    生物相容性交联聚合物与可视化试剂

    公开(公告)号：US07592418B2

    公开(公告)日：2009-09-22

    申请号：US12069821

    申请日：2008-02-13

    申请人： Chandrashekhar P. Pathak ,  Amarpreet S. Sawhney ,  Peter G. Edelman

    发明人： Chandrashekhar P. Pathak ,  Amarpreet S. Sawhney ,  Peter G. Edelman

    IPC分类号： C09F15/00 ,  C07K1/00 ,  C08G63/48 ,  A61K47/30

    CPC分类号： A61K47/34 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/74 ,  A61K47/42 ,  A61L24/106 ,  A61L27/18 ,  A61L27/50 ,  A61L31/06 ,  C07K14/75 ,  C08G63/08 ,  C08G63/912 ,  C08L89/00 ,  G06K7/10831 ,  G06K2207/1016 ,  C08L2666/02

    摘要： Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants. Visualization agents may be included with the crosslinked polymers.

    摘要翻译： 公开了生物相容的交联聚合物及其制备和使用的方法，其中生物相容的交联聚合物由具有能够原位反应和交联的亲电子和亲核官能团的水溶性前体形成。 制备生物相容的交联聚合物可生物降解或不生物降解的方法与控制降解速率的方法一样。 交联反应可以在器官或组织上或身体外的原位进行。 用于这种生物相容性交联聚合物及其前体的应用包括药物的受控递送，术后粘连的预防，医疗装置如血管移植物，伤口敷料和手术密封剂的涂覆。 可交联剂可以与交联聚合物一起包含。

    Therapeutic fibrin-derived peptides and uses thereof
    49.
    发明授权
    Therapeutic fibrin-derived peptides and uses thereof 有权

    公开(公告)号：US07494973B2

    公开(公告)日：2009-02-24

    申请号：US11542050

    申请日：2006-10-03

    申请人： Peter Petzelbauer

    发明人： Peter Petzelbauer

    IPC分类号： A61K38/00

    CPC分类号： A61K38/363 ,  A61K39/00 ,  C07K5/0806 ,  C07K5/1008 ,  C07K14/75

    摘要： The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R1 and R2 are either the same or different, wherein R1 and R2 are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z1 is selected from the group consisting of histidine and proline, wherein Z2 is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids. The invention also relates to methods using the peptides of the present invention in the treatment of inflammation.